Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsThe latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRExploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsConcurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.The quest to overcome resistance to EGFR-targeted therapies in cancer.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Non-Small-Cell Lung CarcinomaThe effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-AnalysisIdentification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutationPrognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysisThe relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsThe impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.The pharmacogenomics of drug resistance to protein kinase inhibitors.Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Current status of research and treatment for non-small cell lung cancer in never-smoking females.ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma.Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.Malignant mixed ovarian germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case reportCombined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
P2860
Q26744339-86D88EE5-66A3-434D-A03F-F89C618B098CQ26823305-27836B79-2B64-4305-B5DB-EE9FCA2FDB58Q28077340-F68644AB-BC61-4D45-8ADF-3BE1CBB7B7FAQ28079320-A6467B70-A70D-490C-90B3-816CFC592A30Q28086993-E69FBFB5-393D-4ED8-9555-9CF66946C35AQ33553528-473BC2C1-7B2C-4011-A85A-BD139D51045DQ33648747-157E4F96-260E-4A03-80DB-FCBE24007BA6Q33725976-B07049DE-072D-4F00-8B56-282D10869771Q33808203-50B9CDF7-D2DB-44D8-97C3-4C4890D588B0Q33873206-3239D6FF-1C97-4061-BD81-51B714CA3245Q35740819-657E23D5-9D52-4034-B5EB-236F347CC642Q36194044-6E829EBC-5B5F-46CA-8051-0552FC2684A0Q36276264-50DF6AAB-71CA-4ADD-98BA-ABA33E378B42Q36399028-A71919F0-FAA6-47E6-BFE5-48DDD5FC00B3Q36413266-9D05A6C8-67FD-48C6-AA33-9803A31828F2Q36427377-17F7A6F9-A7BC-4D92-81AD-60C28C0FF8E9Q36540405-99616579-1202-4E70-B6C7-E0193C4671ABQ37528193-314DB77D-57C0-4C62-9961-D3918B60A87BQ37702099-86931543-F883-4D1A-B92B-CE1D39143193Q37708873-B1BFDCA6-3E79-4995-AD49-141B8A1F4907Q38745430-90A20A2A-AE09-440C-863B-400607A43695Q38806879-AD00500C-7BF7-4008-A574-819B9D6DADAAQ38952751-74D89820-15D9-401C-B0BF-109AD6113CD3Q38956309-BEF2AC7A-0042-44CD-9D92-AE350EC4323FQ39129178-0563EE82-199D-4D32-B834-5B0B7A103049Q39298725-1280F9AC-8C86-4BE9-9913-9EB5A4744B90Q41037400-F9CB5222-76ED-4DC5-8E23-CD7FCF4BCB15Q45903443-A2548E37-8577-4006-9FAF-5E15FE40F766Q47159366-18EBD0E9-487F-4402-8000-F24A662FEE82Q47220604-9D8AED4C-40F6-4CA4-9D5D-32008376643DQ47780922-1FAA74CA-9C8A-4456-92BE-30FABAFF6EA7Q48021721-6B81E962-963A-46C1-9020-E9965CA15EFAQ48356930-6F71BCFC-E926-4E6F-A271-6AD53AF72329Q51034792-F84851ED-9B45-44E1-9581-0753619397E4Q55025386-F04DC75A-57F0-45A0-BAFE-C6838CBE704CQ55070789-F7D766AD-8DC1-4DC3-BE4D-69A4BDEC5E08Q57815599-386BA6EA-5EAE-447A-B101-4346E8B0C808Q58735770-19F5B17B-D371-4DF1-B3D5-6B7D7C274D0E
P2860
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Primary resistance to epiderma ...... tations: an exploratory study.
@en
Primary resistance to epidermal growth factor receptor
@nl
type
label
Primary resistance to epiderma ...... tations: an exploratory study.
@en
Primary resistance to epidermal growth factor receptor
@nl
prefLabel
Primary resistance to epiderma ...... tations: an exploratory study.
@en
Primary resistance to epidermal growth factor receptor
@nl
P2093
P356
P1433
P1476
Primary resistance to epiderma ...... tations: an exploratory study.
@en
P2093
P304
P356
10.1093/ANNONC/MDT127
P577
2013-04-04T00:00:00Z